New pill shows promise for anemia in kids with kidney disease

NCT ID NCT05682326

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called daprodustat in children aged 3 months to under 18 years who have anemia due to chronic kidney disease. The goal was to see how the drug moves through the body and if it is safe. Only 4 children took part, and they received the drug for up to 52 weeks. The study looked at side effects and changes in red blood cell levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daprodustat
What this could lead to: If successful, this could provide a new treatment option for anemia in children with chronic kidney disease, potentially reducing the need for injections.
What could go wrong: This was a very small study with only 4 participants, so results may not apply to all children. The drug also carries risks like blood clots and high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia anemia due to chronic disorder chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAEMIA

Contacts and locations

Locations

GSK Investigational Site

Aichi, 466-8650, Japan
GSK Investigational Site

Saitama, 330-8777, Japan
GSK Investigational Site

Tokyo, 162-8666, Japan
GSK Investigational Site

Yangsan, 50612, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.